Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) EBIT: 2011-2024

Historic EBIT for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to -$302.6 million.

  • Ptc Therapeutics' EBIT rose 105.53% to $3.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $775.9 million, marking a year-over-year increase of 677.47%. This contributed to the annual value of -$302.6 million for FY2024, which is 31.16% up from last year.
  • As of FY2024, Ptc Therapeutics' EBIT stood at -$302.6 million, which was up 31.16% from -$439.5 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' EBIT ranged from a high of -$302.6 million in FY2024 and a low of -$447.4 million during FY2022.
  • Moreover, its 3-year median value for EBIT was -$439.5 million (2023), whereas its average is -$396.5 million.
  • Per our database at Business Quant, Ptc Therapeutics' EBIT crashed by 79.04% in 2020 and then soared by 31.16% in 2024.
  • Ptc Therapeutics' EBIT (Yearly) stood at -$431.8 million in 2020, then increased by 13.28% to -$374.4 million in 2021, then dropped by 19.49% to -$447.4 million in 2022, then grew by 1.77% to -$439.5 million in 2023, then spiked by 31.16% to -$302.6 million in 2024.